Who
John J. Kirby
Interim CFO
Company insider
Files Form 4 as: Interim CFO, Verrica Pharmaceuticals; Chief Financial Officer, Aceragen; V.P., Chief Accounting Officer, Viropharma.
In numbers
- Trades disclosed
- 35
- Buys
- 3
- Sells
- 5
- Bought
- $70K
- Sold
- $23K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 20 Aug 2012
- Last trade
- 18 Aug 2026
- Last filed
- 18 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Aug 2026filed 18 Aug 2026 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $25K5,000 at $4.93 | filing |
| 18 Aug 2026filed 18 Aug 2026 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $25K5,000 at $4.93 | filing |
| 23 Dec 2025filed 30 Dec 2025 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 25 Nov 2025filed 25 Nov 2025 | VRCA Verrica Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code P | —884 | filing |
| 25 Nov 2025filed 25 Nov 2025 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $15K3,536 at $4.24 | filing |
| 6 Nov 2024filed 6 Nov 2024 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —54,267 at $0.00 | filing |
| 20 Jan 2023filed 2 Feb 2023 | Aceragenoption or derivative | SEC FORM 4 Code A | —25,400 at $0.00 | filing |
| 6 Jan 2023filed 10 Jan 2023 | Idera Pharmaceuticals | SEC FORM 4 Code A | —399,218 at $0.00 | filing |
| 6 Jan 2023filed 10 Jan 2023 | Idera Pharmaceuticals | SEC FORM 4 Code F | $85K119,957 at $0.71 | filing |
| 6 Jul 2022filed 7 Jul 2022 | Idera Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —66,500 at $0.00 | filing |
| 1 Apr 2022filed 4 Apr 2022 | Idera Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —41,500 at $0.00 | filing |
| 24 Jan 2022filed 26 Jan 2022 | Idera Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 17 Dec 2021filed 21 Dec 2021 | Idera Pharmaceuticals | SEC FORM 4 Bought | $6,20010,000 at $0.62 | filing |
| 8 Jul 2021filed 12 Jul 2021 | Idera Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —66,500 at $0.00 | filing |
| 25 Mar 2021filed 29 Mar 2021 | Idera Pharmaceuticals | SEC FORM 4 Sold | $8,8756,250 at $1.42 | filing |
| 12 Jan 2021filed 12 Jan 2021 | Idera Pharmaceuticals | SEC FORM 4 Sold | $7,1441,693 at $4.22 | filing |
| 8 Jan 2021filed 12 Jan 2021 | Idera Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —51,000 at $0.00 | filing |
| 5 Jan 2021filed 6 Jan 2021 | Idera Pharmaceuticals | SEC FORM 4 Sold | $3,362862 at $3.90 | filing |
| 21 Jul 2020filed 23 Jul 2020 | Idera Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 10 Jan 2020filed 14 Jan 2020 | Idera Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
News
Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit FacilityVRCA · manilatimes.net · 22 Oct 2026
0 headlines in the last 90 days name John J. Kirby; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.